The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Long-term follow-up results of the ZUMA-1 trial of anti-CD19 CAR T-cells for non-Hodgkin lymphoma
The latest CAR T-cell data was highly anticipated at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Speaking from the meeting, Sattva Neelapu, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes the data he presented on the long-term follow-up of the ZUMA-1 study (NCT02348216) of the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel; KTE-C19) for patients with refractory aggressive non-Hodgkin lymphoma (NHL).
